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Abstract: Treatment rules based on individual patient characteristics that
are easy to interpret and disseminate are important in clinical practice.
Properly planned and conducted randomized clinical trials are used to con-
struct individualized treatment rules. However, it is often a concern that
trial participants lack representativeness, so it limits the applicability of
the derived rules to a target population. In this work, we use data from a
single trial study to propose a two-stage procedure to derive a robust and
parsimonious rule to maximize the benefit in the target population. The
procedure allows a wide range of possible covariate distributions in the tar-
get population, with minimal assumptions on the first two moments of the
covariate distribution. The practical utility and favorable performance of
the methodology are demonstrated using extensive simulations and a real
data application.
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1. Introduction
In the new era of personalized medicine, it has been advocated that treat-
ments should be recommended according to individual patient characteristics
to account for considerable heterogeneity among patients’ responses to differ-
ent treatments (Hayes et al., 2007; Hamburg and Collins, 2010). Randomized
clinical trials (RCTs) are ideal for constructing such rules, since they provide
internal validity by ensuring consistency, positivity and no unmeasured con-
founders (Greenland, 1990; Hernán and Robins, 2006) that may be violated in
observational studies.
Sophisticated statistical methods have been developed to estimate optimal
individualized treatment rules using data from randomized trials. Regression-
based methods estimate outcome as a function of patient covariates and treat-
ment, and then select the treatment that maximizes the predicted outcome for
each individual (Brinkley et al., 2010; Qian and Murphy, 2011; Kang et al.,
2014). Some recent developments directly search for the individualized treat-
ment rules that maximize the benefit for future patients (Zhang et al., 2012;
Zhao et al., 2012). When the primary outcome of interest is survival time sub-
ject to right censoring, some methods have been proposed in this regard using
either regression-based methods (Goldberg and Kosorok, 2012; Huang et al.,
2014) or direct search methods (Zhao et al., 2015).
The derived optimal rules sometimes are complex and nonlinear, so they are
highly variable and may not be practically useful. To better inform clinical prac-
tice, it is more desirable that a recommended treatment rule be easy to interpret
and disseminate. As suggested in Orellana et al. (2010), the class of practically
enforceable candidate regimes is significantly smaller than the class of arbitrary
functions of covariates. Usually these regimes are comprised of functions that
only depend on a small set of covariates, and are indexed by a set of finite di-
mensional parameters. Statistically, Qian and Murphy (2011) used a rich linear
basis for better modeling the outcome, with a sparsity penalty imposed to pre-
serve the parsimoniousness of the resulting rule, while most works considered
and recommended rules from a linear functional class.
Unfortunately, it has been well known that the RCT may have limited gen-
eralizability when the distribution of treatment effect modifiers in trial partic-
ipants differs from the one in a target population (Buchanan et al., 2016). A
parsimonious treatment rule constructed from trial data using current methods
cannot be directly carried over to a target population, when the population char-
acteristics are different between the two. Some attempts have been made to ad-
just population difference using inverse probability-of-selection weight method
(Cole and Stuart, 2010). This, however, requires complete knowledge of pop-
ulation selection mechanism, and it is yet to be extended to the context of
developing optimal treatment rules.
In this paper, we aim to robustify the treatment rule from a trial so that the
robustified rule is (1) parsimonious (linear in patient features in particular); (2)
still maximizes a general benefit criterion when applied to the target popula-
tion. We provide a new framework, called minimax linear decision (MiLD), to
robustify the treatment rule. MiLD enables the construction of a linear rule that
optimizes the general benefit function in the target population, allowing differ-
ences between the target and the trial populations in the means and covariances
in treatment effect modifiers. It can be further extended to construct nonlinear
rules using the ‘kernel trick’, which avoids the explicit feature mapping but only
relies on a kernel function to learn a nonlinear decision boundary. Regardless,
MiLD requires no further assumptions beyond the first two moments of the
covariate distributions. Moreover, our developed framework is applicable to all
types of outcomes.
The remainder of the paper is organized as follows. In Section 2, we for-
mulate the problem of finding a robust and parsimonious treatment rule using
data from a clinical trial. The proposed method, MiLD, is then developed to
optimize a general benefit function in the target population, allowing the covari-
ate distribution to be different between the two populations. Consistency and
convergence rate results are established for the proposed method. We present
simulation studies to evaluate performances of the proposed method in Section
4. We further illustrate the method using a data example from a US NIH funded
SWOG trial on castration-resistant prostate cancer patients in Section 5. The
proofs of theoretical results are given in the Appendix.
2. Methodology
2.1. Background and the optimal treatment rule
Let T denote the outcome of interest, A ∈ {−1, 1} denote a binary treatment,
and X = (X1, ..., Xm)
ᵀ ∈ Rm denote patient covariates. We assume the di-
mension is small to moderate, and fixed. The outcome could be a continuous,
discrete, or time-to-event outcome subject to censoring. A treatment regime
d ∈ D is a function mapping from the space of X to the space of treatments.
A future patient with X = x is then assigned with treatment d(x). Let T (a)
denote the potential outcome under treatment a ∈ {−1, 1} (Rubin, 1978), and
T (d) = T{d(X)} be the potential outcome under the rule d for the given co-
variate X. The quality of d can be measured by the marginal mean outcome
E{T (d)}, which represents the trial population mean outcome were all patients
in the trial population to receive treatment according to d. We denote this quan-
tity as V(d), which is also called the value function of d. The optimal treatment
regime d∗ maximizes V(d) over all possible d. We assume that in the trial,
(A1) P (A = a|X) > 0 with probability one for a ∈ {−1, 1};
(A2) {T (−1), T (1)} are independent of A conditional X;
(A3) consistency so that T (a) =
∑
a I(A = a)T .
Since V(d) = E{T (d)} = EX(E[T{d(X)}|X}]), where the outer expectation
EX(·) is taken with respect to the marginal distribution of X in the trial
population, the optimal treatment for any patient with characteristics x is
d∗(x) = argmaxa∈{−1,1}E{T (a)|X = x} when there is no restriction of the
functional form of the rule. These assumptions are typically standard and sat-
isfied in randomized clinical trials (Robins et al., 2000), because application of
the intervention to any individual is under the control of the investigator. This
is however, not guaranteed in observational studies. For example, consistency
assumption can be violated given that there could be variations of treatment,
and each of them may have a different causal effect on the outcome. In addition,
noncom- pliance can be severe in observational studies, where some subjects may
never take what they are asked to take. If (A1)-(A3) are satisfied, the optimal
treatment rule is
d∗(x) = sign{f∗(x)}, where f∗(x) = E(T |X = x,A = 1)−E(T |X = x,A = −1).
To assess the overall benefit of the obtained rule when applied to the target
population, we let pX(x) denote the distribution of X in the trial population,
and qX(x) denote the distribution of X in the target population, which is not
necessarily the same as pX(x). Furthermore, we assume
(A4) the support of qX(x) is contained in the support of pX(x), i.e., there is
no under-coverage in the trial study;
(A5) the potential outcome mean given X is the same between the trial popu-
lation and the target population. Thus, the treatment works the same in
both populations.
Thus, the only difference between the two populations is due to the covariate
distributions. Let P q denote the distribution of X in the target population and
P p denote the distribution of X in the trial population. Let Ẽ denote the expec-
tation is taken with respect to the distribution of X in the target population.
Under (A4) and (A5), it is easy to observe that the expected outcome of rule
d(X) for the target population is
Ṽ(d) = Ẽ[T{d(X)}] =
∫












where EX [·] denotes the expectation under X ∼ pX(x). Consequently, the op-
timal rule obtained from the trial population, d∗, is also the optimal for the
target population if there is not any restriction to the formulation in d∗.
2.2. A General Quality Value of Treatment Rules for the Target
Population
We propose a general criterion assessing the quality of a decision rule for the
target population, which includes both the value function and the correct al-
location rate to the optimal rule as special cases. For a given rule d(X), the
proposed quality assessment in the target population is defined as
B̃(d) = Ẽ[W (X)I{d(X) = d∗(X)}],
where W (X) is a non-negative function, essentially a reward if the treatment
rule d(x) is the optimal.
The quality value in the definition has a different interpretation depending
on the choice of W (x). For example, let W (x) = W1(x) = E{T |A = d∗(x), X =
x} − E{T |A = d∗(x), X = x} = |f∗(x)|. That is, for subject with covariate
X = x, W (x) is the gain if he/she follows treatment rule d∗. B̃(d) achieves
optimal if d = d∗. This is because B̃(d) = Ṽ(d)+Ẽ{T (−d∗)}. Hence, maximizing
B̃(d) is equivalent to maximizing the value function in the target population.
If we set W (X) = W2(X) ≡ 1, then B̃(d) = P̃{d(X) = d∗(X)}, and the
criterion corresponds to the correct allocation rate of the optimal treatment.
Additionally, in practice, W (X) could allow more general trade off between the
benefit of optimal treatment and the relative cost of giving optimal treatment
to patients instead of standard care. In this paper, we will focus on the choice
of W = W1 and W2.
2.3. Learning Robust Linear Rules for the Target Population
In many practices, since the set of enforceable treatment rules are usually restric-
tive and cannot be arbitrary, a parsimonious and interpretable decision rule is
preferred. In particular, we focus on a linear decision rule, i.e., d(x) = sign{f(x)}
where f(x) = xᵀβ1+β0. A patient x is assigned to treatment 1 if xᵀβ1+β0 ≥ 0
and treatment −1 otherwise. For example, let the potential outcome model
be E[log{T̃ (a)}|X] = (2I[{3X/4 + sin(X)/4 − 2}2 − 1] − 1)a. The optimal
rule d∗(x) = 1 if 3x/4 + sin(x)/4 − 1 ≤ 0 or 3x/4 + sin(x)/4 − 3 > 0, and
d∗(x) = −1 otherwise. Consider the space of linear decision rules with DL =
{d(X) = sign(β0 + β1X), β0, β1 ∈ R}. Therefore d∗(x) is highly nonlinear, and
d∗(x) /∈ DL. Assume that X ∼ N(2, 1) and X ∼ N(4, 1) in the trial and target
population, respectively. Then the optimal linear rule is d∗L(X) = sign(X − 0.9)
using the trial data. However, sign(−X+0.28) should be the optimal linear rule
in the target population, which lead to a benefit of 0.997, versus a benefit of
-0.387 using the optimal rule derived from the trial data. Hence, the optimal
linear rules could be substantially different between the two populations.
We should note that unless the true optimal rule is linear itself, once restricted
to such a class of linear rules, the optimal rule within this class may no longer be
the optimal for the target population, since both pX(x) and qX(x) can be very
different. It is thus desirable to guarantee that B̃(d) is not small, regardless of X
and which treatment is optimal; and ideally, the larger the better. To this end,
we propose the following method, namely, Minimax Linear Decisions (MiLD).
Note that
B̃(d) = Ẽ[W (X)I{d(X) = 1}|d∗(X) = 1]P̃{d∗(X) = 1}
+Ẽ[W (X)I{d(X) = −1}|d∗(X) = −1]P̃{d∗(X) = −1}.
We introduce a lower bound α on Ẽ{W (X)I{sign(Xᵀβ1 + β0) = j|d∗(X) = j},
j = ±1, which represents the expected benefit that would have been obtained
if the patients were to receive treatment j, whose optimal treatments would
indeed be j in the target population. Hence, α controls the worst case overall
benefits for each group, and we set the same lower bound for both quantities
for simplicity. We then consider the following optimization problem:
max
α,β1,β0
α subject to inf
X∼f1
Ẽ {W (X)I(Xᵀβ1 + β0 ≥ 0)|d∗(X) = 1} ≥ α,(1)
inf
X∼f−1
Ẽ {W (X)I(Xᵀβ1 + β0 < 0)|d∗(X) = −1} ≥ α,
where f1 and f−1 are the density of X in patients whose optimal treatment
are 1 or −1 respectively. That is, we want to guarantee the quality of being
given optimal treatment as large as possible among those who should indeed be
treated with the same treatment.
Let q̃j(x) denote the density of X for patients with d
∗(X) = j, j = ±1 in the
target population. Then
Ẽ {W (X)I(Xᵀβ1 + β0 ≥ 0)|d∗(X) = j} =
∫
W (x)I(xᵀβ1 + β0 ≥ 0)qj(x)dx
∝ P̌ (X†ᵀβ1 + β0 ≥ 0),
where the density of X† is proportional to q̃j(x













β1 + β0 < 0) ≥ α,
where f†1 and f
†
−1 are the density of X
† in patients with optimal treatment
being 1 or −1 respectively.
However, f†1 and f
†
−1 could be very different, and difficult to characterize
based on the trial data. We propose to quantify the difference between the target
population and the trial population in terms of the first two moment conditions,
without making any specific distributional assumptions for the two populations.
In other words, the covariate moments of X† in patients with d∗(x) = j, j = ±1
in the target population could be different from that of the trial population to
some degree.
Suppose that the means of covariate X† are μ̃†j , and intraclass covariance
matrices are Σ̃j for patients with d
∗(X) = j in the target population, and μ†j
and Σ†j , j = ±1, respectively, in the trial population under the new density. We


















j‖F ≤ ρj}, j = ±1. (3)
Here, ν ≥ 0 and ρj ≥ 0 are known constants, and ‖ · ‖F is the Frobenius norm
defined as ‖M‖2F = Tr(MᵀM). Such conditions define the closeness of the target
population to the trial population. U+j suggests that the mean μ̃
†
j in the target
population belongs to an elliptical region around μ†j with shape determined by
the covariance Σ̃†j , j = ±1. The covariance matrix Σ̃
†
j , centered around Σ
†
j , can
also vary to certain degrees. Clearly, the larger ν or ρj , the more different the
two populations are. (2) is consequently written as
max
α,β1,β0

















β1 + β0 < 0) ≥ α.
This yields a linear decision rule that safeguards against the possible difference
of the distribution of X between the trial and the target populations. Such
robustness of the treatment regime estimation is mainly due to the minimum
requirements on the means and covariances. The above objective function has
a similar form to the minimax probability machine techniques developed in
Lanckriet et al. (2003), and their techniques for deriving the optimal linear rule
can be employed if (μ̃†j , Σ̃
†
j), j = ±1, were known. The key step is to recognize





β1 + β0 ≥ 0) ≥ α, holds if and only if
β0 + μ̃
†ᵀ




jβ1, j = ±1, (5)
by applying the generalized Chebychev inequality (Marshall and Olkin, 1960),
where κ(α) =
√
α/(1− α) (Lemma 1, Lanckriet and others (2003)). The con-
straint (5) is imposed on the distance with respect to the mean of the covariates
within the class, taking into account the effect of the covariance matrices, which
could be representable of the class. In other words, we search a line such that
the normalized margin between the means of classes is as large as possible.
Consequently, (4) is equivalent to
max
α,β1,β0
α subject to β0 + μ̃
†ᵀ























−1 + ρ−1Ip)β1, (6)




−1) = 1. We can eliminate the equality constraint in (6)







F is a p× (p− 1) matrix. Let h denote the position of the maximum element
in μ†1 − μ
†







−1) inserted into the h
th row. We can see that F is
an orthogonal matrix whose columns span the subspace of vectors orthogonal
to μ†1 − μ
†











−1 + ρ−1Ip)(β10 + Fu).
The lower bound on the worst case allocation rate α∗ = (κ∗−ν)2/{1+(κ∗−ν)2},















and ν is defined in (3). More details can be found in the Appendix.
Remark 1 Although the MiLD is proposed to identify a robust linear rule, it can
be easily generalized using nonlinear kernel functions. We seek a decision rule
in the form of f(x) = ϕ(x)ᵀβ1 + β0, where ϕ(x) is a set of basis functions. The
kernelization of the proposed approach is possible because the objective function
(6) can be expressed in terms of inner products between different X ′s. Hence,
the objective and constraint can be expressed in terms of inner products of ϕ(X).
Subsequently, we can compute the robust nonlinear rule by slightly modifying the
algorithm.
2.4. Estimating robust rules using empirical data
To solve for the minimax linear decisions given the observed data from a clinical
trial, we first need to estimate (μ†j ,Σ
†
j), j = ±1, which depends on both the
optimal treatment rule d∗(x) and the weight W (X). A three-step procedure is
outlined below.
Step 1. Estimate d∗(x) using a nonparametric method with the trial data,
denoted by d̂(x).
Step 2. Estimate (μ̃†j , Σ̃
†





Step 3. Implement MiLD based on the estimated (μ̂†j , Σ̂
†
j).
In Step 1, there are several ways to estimate d∗. Indirect estimation methods
model the response as a function of X and A, and select treatment, which maxi-
mizes the predicted mean outcome (Qian and Murphy, 2011). Since a consistent
estimator d̂(x) is required to guarantee the performance, a flexible nonparamet-
ric method in Step 1 is preferred. For example, support vector machine and sup-
port vector regression can be used to estimate E(T |X,A) for binary and contin-
uous outcomes respectively. Alternatively, outcome weighted learning proposed
in Zhao et al. (2012) circumvents the two-step procedure by directly optimizing
the value function. We can employ a kernel function to induce nonlinearity in
obtaining the initial estimator d̂.
In a cancer clinical trial, it is common that the primary endpoint is survival
time that subjects to censoring. Given that d∗(x) is invariant over the covariate
distribution, we suggest utilizing flexible nonparametric machine learning meth-
ods. In particular, we will use the random forest survival tree method (Ishwaran
et al., 2008) to estimate E(T |X,A), an ensemble tree method that extended ran-
dom forest method (Breiman, 2001) for analysis of right-censored survival data.
It uses independent bootstrap samples to grow trees by randomly selecting a sub-
set of variables at each node and splitting the node using a survival criterion ad-
justing for censoring status. The ensemble estimated cumulative hazard function
is the average of the Nelson-Aalen estimator for each case’s terminal node. Easy-
to-use software is available on R CRAN (https://cran.r-project.org). We
can estimate E(T |X,A) correspondingly via E(T |X,A) =
∫ τ
0
P (T > t|X,A)dt.
Then d̂(x) = sign{f̂(x)}, where f̂(x) = Ê(T |X = x,A = 1) − Ê(T |X = x,A =
−1).
To estimate (μ†j ,Σ
†
j) with a general weight W (x), we treat it as a multi-
plicative adjustment to X where we now sample from a density proportional
to pX(x)W (x) instead of pX(x). This motivates us to employ techniques from
importance sampling to estimate (μ†j ,Σ
†
j), j = ±1. In particular, μ
†




i=1 XiW (Xi)I{d̂(Xi) = j}∑n
i=1 W (Xi)I{d̂(Xi) = j}
;





W (Xi)I{d̂(Xi) = j}∑n
i=1 W (Xi)I{d̂(Xi) = j}
]2
(Xi − μ̂†j)ᵀ(Xi − μ̂
†
j).
In our case, we choose
W (x) = Ŵ1(x) = Ê{T |A = d∗(x), X = x} − Ê{T |A = d∗(x), X = x}
=
∣∣∣Ê{T |A = 1, X = x} − Ê{T |A = −1, X = x}∣∣∣
= |f̂(X)|
or W (X) = W2(X) ≡ 1.
Provided with the estimated (μ̂†j , Σ̂
†
j), j = ±1, we solve for the robust linear
treatment regimes in Step 3 using the procedure outlined in Section 2.3. In
particular, estimates will be plugged in for μ†j and Σ
†
j , j = ±1 and related
quantities. We obtain β̂1 and β̂0 accordingly.
2.5. Choices of (ν, ρj)
Sometimes pilot data from the target population or the general patient popula-
tion data are available. We can use this information to choose ρj and ν. First
we obtain d̂(x) as an initial estimate of d∗(x) using the trial data. Based on
this preliminary decision boundary d̂(x), we can estimate μ̃†j and Σ̃
†
j , j = ±1,
denoted as μ̂j and Σ̂j , for a target population using the pilot data. Then we






j (bμ̂j)/2, where b is a constant char-
acterizing the potential differences between two population means, as well as
the norm of the covariance matrix. If relevant data is not available, we can con-
duct sensitivity analyses on different combinations of (ν, ρj), and assess how the
changes in (ν, ρj) will influence the resulting decision rules and the worst-case
allocation rates.
3. Theoretical results
In this section, we will establish some theoretical properties of the proposed
MiLD method. Assume that (Xi, Ai, Ti), i = 1, ..., n, are i.i.d observations
from the trial. Additionally, we assume that
Assumption 1 All covariates are bounded such that |X| ≤ M .
Assumption 2 Let β∗1 be the unique solution to (1). β
∗
1 lies in the interior of
a compact set B.
We assume the following condition on f∗(x) = E(T |X = x,A = 1) −
E(T |X = x,A = −1):
Assumption 3 Margin condition: there exist K1, γ > 0 such that for all t > 0
P̃ (|f∗(X)| ≤ t) ≤ K1tγ .
Assumption 4 f̂ converges to fm, which could be different from f∗. The con-
vergence rate of estimated f̂ to fm satisfies ‖f̂ − f∗‖2 = Op(rn), where ‖f‖2 =
E{f(X)2}1/2 and the expectation is taken with respect to the distribution in the
trial data.
Assumption 5 The difference of the covariates is uniformly bounded
max
i,i′≤n
|Xi −X ′i| ≤ CX ,
for some constant CX > 0.
Assumption 6 Let f̆i(x) be the estimate of f
∗(x) using the Step 1 data except
that the ith observation (xi, ai, ti) is replaced by an independent observation
(x̆i, ăi, t̆i). We assume that
sup
X
|f̆i(X)− f̂(X)| ≤ ρ/n
for some constant ρ.
Assumption 3 is an analogue of the well-known margin condition (Tsybakov,
2004), which is commonly used to characterize the noise around the decision
boundary in a binary classification problem. Here, the assumption describes the
distribution of f∗(X) when X is near the boundary {x : f∗(x) = 0} in the target
population, which usually contains more noise, and γ controls the size of these
regions. Particularly, larger values of γ mean that the two treatment effects are
less likely to be similar, and it is easier to distinguish patients who would have
benefited from one treatment from those who would have benefited from the
other. Usually, γ ∈ [0,m] for a smooth contrast function f∗(x), unless f∗(x)
does not cross 0 at any point, i.e., all the patients benefit from one treatment
(Audibert et al., 2007). For example, if X ∼ Uniform[−1, 1], P (A = 1|X =
P (A = −1|X) = 1/2) and E(T |X,A) = XA, then γ = 1. The bounded covari-
ate assumption, Assumption 5, is satisfied in most real applications. Assumption
6 indicates that small changes in the data will only lead to small changes in the
estimates. For example, if we use Cox regression with nonlinear basis functions,
or nonparametric kernel estimators, this condition will be satisfied (Devroye
et al., 2013). The following results are proved in the supplementary materials
(Zhao et al., 2019).







The first term reflects the approximation error due to the initial estimator
f̂ . If f̂ is a consistent estimator of f∗, where f∗ = fm, then the first term will
disappear. The other terms bound the stochastic error, which arises from the
variability inherent in a finite sample size, which captures the efficiency loss due
to the first stage estimation. As an example, if we use random forest to estimate
the required quantities, rn = n
−θ with θ = 0.752{S log(2)+0.75} under some mild
assumptions, where S denotes the number of strong features used in the esti-
mating process (Biau, 2012). The theorem indicates that the convergence rate of
the estimated linear treatment rules depends on the the initial treatment rule,
and the behavior of f∗(x) in the neighborhood of the boundary. For example, if
a kernel estimator is used, the optimal rate of rn would be n
−2/(m+4), and the
conclusion rate is n−4γ/(m+4)(γ+2).
4. Simulation Studies
We conduct extensive simulations to evaluate the proposed methods. In all sce-
narios, the dimension of the covariate space is 10. Binary treatments A are
generated from {−1, 1} with equal probability. Three different scenarios are
presented, with outcomes generated as follows.
Scenario 1. We simulate the first half of patients from X1, X2 ∼ N(1, 1),
X3, . . . , X10 ∼ N(0, 1) and the second half of patients with X1, . . . , X10 from
N(0, 1). The survival time is the minimum of τ = 0.5 and T̃ , where T̃ is gener-
ated with
log T̃  = exp{0.6 ∗ X1 − 0.8 ∗ X2 + A ∗ c(X)} + log ε.
Here, c(X) = 1 for the first half of patients and c(X) = −1 for the other half,
and ε is generated from an exponential distribution with mean 1. Censoring time
C is generated from Uniform[0, 1]. The censoring percentage is around 24%. The
optimal decision boundary is d∗(X) = sign(X1 +X2 − 1).
Scenario 2. X1, . . . , X10 are generated from N(0, 1). The survival time is the
minimum of τ = 4 and T̃ , where T̃ is generated with the hazard rate function
λT̃ (t|X,A) = exp[0.6X1 + 0.8X2 − 1 + {2X1 + 3(X2 + 1)
2 − 2}A].
Censoring time C is generated from Uniform[0, 5]. The censoring percentage is
around 42%. The optimal decision boundary is d∗(X) = −sign{2X1 + 3(X2 +
1)2 − 2}.
Scenario 3. X1, . . . , X10 are generated from N(0, 1). The survival time is the
minimum of τ = 4 and T̃ , which is generated with
log(T̃ ) = X1 +X2 + 1 +A(2X
3
1 + 2X2 + 0.5) +N(0, 1).
Censoring time C is generated from
log(C) ∼ X1 +X2 +X3 +N(0, 1).
The censoring percentage is around 51%. The optimal decision boundary is
d∗(X) = sign(2X31 + 2X2 + 0.5).
We also consider settings where there is a mismatch between the trial partici-
pants and the target population, and we will denote these mismatch scenarios as
Scenarios 1’, 2’, and 3’ respectively. In Scenario 1, half of the patients will gain
benefits from treatment 1 in both populations. We modify it in Scenario 1’ such
that the proportion of patients with d∗(x) = 1 is 1/3 in the trial population,
and 1/2 in the target population. In Scenario 2’, we let the covariate distri-
bution in the trial data with X1 ∼ N(−0.25, 1.5) and other covariates follow-
ing N(0, 1.5), which are different from the distribution in the target population
with all covariates generated from N(0, 1). Eligibility criteria are usually applied
for the trial recruitment, and thus trials might selectively enroll patients from
the target population. Instead of randomly choosing patients for participation
in the trial, patients are selectively enrolled with certain probability, denoted
by π(X), into the trial data. In Scenario 3’, the model for the enrollment is
logit{π(X)} = −2X31 − 1, where logit(t) = log{t/(1 − t)}. Hence, covariates
predictive of participation in the trial could be predictive of treatment effects,
where patients with d∗(x) = 1 are less likely to participate in the trial. Subse-
quently, the covariate distributions in trial data and the target population are
not the same.
We hope to discover a simple linear decision rule of high quality even if
the true treatment effect might be nonlinear. MiLD will be evaluated for this
purpose. In this paper, we utilize random survival forest to obtain the initial
estimate of d∗(x), but other methods can also be applied. Then we apply both
Ŵ1(x) andW2(x) ≡ 1 in MiLD, targeted to optimize the value and the allocation
rate to the optimal rule, respectively. We denote them as MiLD-V and MiLD-P.
The results might be affected with possible deviations between the target and
the trial populations. When we do not have prior information on the target
population, we can vary (ν, ρj) to evaluate the resulting changes. As suggested
in Section 2.5, we set ρj = b‖Σ̂j‖F , ν = {
∑
j(bμ̂j)
ᵀ(Σ̂j+b‖Σ̂j‖F Ip)(bμ̂j)}/2, j =
±1. Here, ‖Σ̂j‖F is the Frobenius norm of Σ̂j , and b is a constant that reflects
the deviations relative to the covariance matrix norms and the means, in the
trial populations. We consider two cases with b = 0 and b = 0.1 for both MiLD-V
and MiLD-P.
We compare the proposed methods to the following two approaches.
1. OWL (outcome weighted learning): we find the best linear decision rule by
directly targeting maximizing the overall expected outcome (Zhao et al.,
2012).
2. COX: we find the linear decision rule based on a Cox regression model,
where interactions between X and A are included.
All methods are performed by deriving the best linear treatment rules using trial
data. We then calculate the misclassification rate under the estimated rules via
Monte Carlo methods. Specifically, a large testing dataset of 10,000 from the
target population is generated. Training datasets representing the trial pop-
ulation are repeatedly simulated, and each time the rules yielded by various
methods are evaluated on this testing set. Different training data sample sizes
n = 250, 500 and 1000 are considered. We report the average misallocation to
non-optimal treatments over 500 replicates. We also report the expected overall
survival of the estimated rules using the derived treatment rules by different
methods in the supplementary materials.
The results in Figures 1–3 present evidence that the proposed methods per-
form well compared with the other methods. The Cox regression method relies
on model fitting, and thus many subjects are recommended the wrong treat-
ments by the resulting linear decision rule, labeled as misallocation rates in
Figures 1–3. Even in Scenarios 1 and 1’ where the optimal treatment rule is
linear, the non-proportional hazards model negatively impacts the performance
of Cox regression. The OWL method in general leads to a larger variability. On
the other hand, both MiLD-V and MiLD-P perform well throughout, and the
results are insensitive to the value of b. The limits of misallocation rates that
MiLD-V and MiLD-P converge to are the lowest among all competitors. It can
be seen that when the trial population is not representative as illustrated in Sce-
narios 1’, 2’ and 3’, MiLD-V and MiLD-P are robust to the bias, and they yield
favorable results. We note that the results in MiLD with b = 0.1, which allows
a larger deviation between the trial and the target population, give a slightly
better result most of the time in these cases. We also illustrate the efficiency
loss due to the first stage estimation of f∗(x) numerically. Details can be found
in supplementary material.
Fig 1. Misallocation rates in Scenarios 1 and 1’ using trial data with sample sizes varying
from 250 to 1000. The misallocation rate is evaluated by using 500 Monte Carlo repetitions.
5. Data Analysis
Prior studies suggest that elevated markers of bone turnover are prognostic for
poor survival in castration-resistant prostate cancer, but their predictive value
for the bone-targeted therapy has not been fully investigated. We illustrate
the proposed methods using data from SWOG 0421 study, a North American
Intergroup phase III trial (participants: SWOG, Eastern Cooperative Oncol-
ogy Group, Cancer and Leukemia Group B/Alliance) for men with metastatic
Fig 2. Misallocation rates in Scenarios 2 and 2’ using trial data with sample sizes varying
from 250 to 1000. The misallocation rate is evaluated by using 500 Monte Carlo repetitions.
castration-resistant prostate cancer. They were randomly assigned in a blinded
fashion in a 1:1 ratio to docetaxel administered every 21 days at a dose of 75
mg/m2 with or without the bone-targeted oral agent atrasentan taken daily for
up to 12 cycles (Quinn et al., 2013; Lara et al., 2014). S0421 enrolled 1038 eli-
gible patients; of these, 855 submitted serum for the bone biomarkers and 778
patients had usable specimens at baseline. After removing missing observations,
the sample size for our analysis is 751, where 371 patients are in the docetaxel
+ atrasentan arm and 380 patients are in the docetaxel + placebo arm.
Fig 3. Misallocation rates in Scenarios 3 and 3’ using trial data with sample sizes varying
from 250 to 1000. The misallocation rate is evaluated by using 500 Monte Carlo repetitions.
Co-primary endpoints in this study were progression-free survival and overall
survival. In our analysis, we use overall survival as our outcome, which is trun-
cated at the end of the study, and could be censored due to loss of follow-up.
We use 10 baseline covariates to inform the optimal treatment rule, including
age (range 40–92), serum prostate-specific antigen (PSA, range 0.1–10414.1), in-
dicator of bisphosphonate usage (61%), indicator of metastatic disease beyond
the bones (55%), indicator of pain at baseline (60%), indicator of performance
status (2-3 versus 0–1, 56% 2-3), and bone marker levels. Four bone markers are
measured, including Bone alkaline phosphatase (BAP, range 1.9–1761.0 u/L),
C-terminal of type 1 collagen (CICP, range 1.4–273.6 ng/mL), N-telopeptides
of type 1 collagen (NTx, range 1.4–480.0 nM) and pyridinoline (PYD, range
0.3–15.0 nmol/L). The distribution of bone marker concentrations and serum
PSA were skewed with a wide range; therefore, we use log transformation for
these variables. All covariates are then standardized for analysis. We intend to
find the optimal linear treatment rule that is robust to a potential difference
between the trial population and the future population.
We compare the proposed methods with Cox regression and OWL method.
Practitioners often directly generalize the results from a clinical trial to the
general patient population. However, It is not uncommon that the participants
in clinical trials are in general more healthier than the patient population, due
to the restrictions on patient eligibility. Hence, in our data analysis, we mimic
this phenomenon by changing the distribution of healthier patients in the trial
population and the target population. We categorize patients to healthier pa-
tients whose serum PSA is below the median level and sicker patients whose
serum PSA is above the median level. We employ a cross-validated type anal-
ysis. At each run, we partition the whole data set into 5 pieces, where 2 parts
of the data are used as training data to estimate the optimal rules, and the
remaining part as the validation set for evaluating the estimated rules. Specif-
ically, each training data set consists of 2/3 healthier patients and 1/3 sicker
patients; on the other hand, each validation set contains 1/3 healthier patients
and 2/3 sicker patients. Thus, there is a substantial discrepancy between the
training set and the validation set, which represents the trial population and
the target population, respectively. The cross-validated values are obtained by
averaging the empirical value on all 3 validation subsets. To adjust for censoring
when calculating the empirical values, we use inverse probability of censoring
weighting techniques, where the empirical value for a treatment decision rule
d is calculated by Pn[Ỹ I{A = d(X)}]/Pn[Ĩ{A = d(X)}], with Ỹ equaling to
ΔY/ŜC(Y |A,X). We use a kernel estimator developed in Li et al. (1999) to
obtain ŜC(t|A,X), which does not require a model assumption. The procedure
is repeated 200 times. The averages and standard errors of these values are re-
ported in Table 1, where a larger value corresponds to a longer expected survival
time. The results show better performances of both MiLD-V and MiLD-P proce-
dures compared to other methods. MiLD-V performs the best perhaps because
it targets to optimize the value directly.
We then apply the proposed methods to the whole data set. The coefficients in
the treatment decision rule recommended by MiLD-V and MiLD-P are presented
Table 1
Mean (s.e.) cross-validated values (days)
COX OWL MiLD-V MiLD-P
b = 0 b = 0.1 b = 0 b = 0.1
749.2 (69.8) 711.1 (71.2) 764.6 (70.2) 765.0 (68.9) 753.5 (69.4) 753.7 (69.4)
“s.e.” denotes standard errors.
Table 2





Baseline serum PSA -0.510 -0.734
Bisphosphonate usage (YES = 1) 0.787 1.235
Metastatic disease beyond the bones (YES = 1) -0.301 0.008
Pain (YES = 1) -0.272 0.050





in Table 2. The results yielded by MiLD-V and MiLD-P are close, where 80%
of the patients receive the same treatment recommendation. In Figure 4(a), we
compare the Kaplan–Meier curves for overall survival between two treatment
arms. There does not appear to be separation. However, when comparing the
group whose treatment assignments were in accordance with the treatments
recommended by MiLD-V or MiLD-P with the other group, the Kaplan–Meier
survival curves show a clear separation, as shown in Figures 4(b) and (c).
6. Discussion
In practice, it is preferable to use interpretable decision rules when communi-
cating with clinical practitioners about treatment recommendation. A canonical
example is linear decision rule, which is attractive because it can be easily under-
stood, and thus can be used to guide future research. Our present work shows
that it is possible to identify high-quality linear decision rule that leads to a
greater overall benefit, even if the truth may be nonlinear. Furthermore, the
proposed method is robust across future populations, taking into account the
fact that the study sample may not be representative.
We consider survival time outcomes in this paper. Such endpoints are critical
in many settings especially in oncology. However, MiLD can be readily applied
for binary or continuous outcomes, provided that we can use existing nonpara-
metric methods to obtain preliminary estimates of the decision boundaries. Pop-
ular methods for binary outcomes include support vector machine and boosting
(Hastie et al., 2009), and for continuous outcomes, we can apply random for-
est (Breiman, 2001) and support vector regression (Vapnik et al., 1997). Our
current proposal suggests an L2 penalty for handling high-dimensional covari-
ates. However, this does not provide sparse solutions. In certain circumstances,
several important variables characterize the optimal treatment rules, where the
means and covariance matrices of those unimportant variables do not matter. It
would be interesting to develop robust methods that conduct variable selection
Fig 4. Kaplan–Meier survival curves of overall survival in castration-resistant prostate cancer
patients: (a) by treatment received; (b) by accordance between treatment recommended by
MiLD-V and treatment received; (c) by accordance between treatment recommended by MiLD-
P and treatment received.
simultaneously, which would eliminate the unimportant variables and further
improve the ease of interpretation. Another interesting extension of the current
work is to consider settings involving more than two treatments. While it is
straightforward to conduct a series of pairwise comparisons, further develop-
ment is required to identify the best rule among all treatments. It will also be
interesting to investigate extensions to Boolean combination of linear rules, i.e.,
rules of the form {X1β11 + β01 ≥ 0} ∩ {X2β21 + β02 ≥ 0}.
Appendix A: Appendix
Solving minimax linear decisions. It follows from the generalized Chebychev




























































† + ρIp)β1, where Ip is the identified


















ρj}, j = ±1, We have β0 + βᵀ1 μ̃
†















j + ρjIp)β1. We thus further rewrite the optimization problem to
max
α,β1,β0
















We will assume that μ†1 = μ
†
−1; otherwise, the above problem is not identifi-
able. We also assume that Σ†j , j = ±1 are both positive definite. Since κ(α) is a


















and these inequalities will become equalities at the optimum. We can eliminate





−1‖22, and F ∈ Rp×(p−1) is an orthogonal matrix whose columns
span the subspace of vectors orthogonal to μ†1 − μ
†
−1. Hence, the optimization







































The lower bound on the worst case allocation rate α∗ = (κ∗− ν)2/{1+(κ∗−
ν)2}, and ν should not exceed κ∗.
Proof of Theorem 1. We first show that |μ̂†j − μ
†
j | = Op(r
2γ
γ+2






n + n−1/2), j = ±1, where W (X) = Ŵ1(X) = |f̂(X)| and
‖A‖ = supx∈X ‖Ax‖2. For the convergence rate in means,
|μ̂†j − μ
†
j | = |PnXf̂(X)I{d̂(X) = j} − PXf∗(X)I{d∗(X) = j}|
≤ |PnXf̂(X)I{d̂(X) = j} −  PXf̂(X)I{d̂(X) = j}|
+ |PXf̂(X)I{d̂(X) = j} − PXfm(X)I{d̂(X) = j}|
+ |PXfm(X)I{d̂(X) = j} − PXf∗(X)I{d̂(X) = j}|
+ |PXf∗(X)I{d̂(X) = j} − PXf∗(X)I{d∗(X) = j}|
= (I) + (II) + (III) + (IV ).
We will use McDiarmid’s inequality to bound (I).∣∣∣∣∣∣ 1n
n∑
k=1

























∣∣∣(xi − x̆i)f̂(xi)I{d̂(xi) = j}+ x̆i{f̂(xi)− f̆i(x̆i)}I{d̂(xi) = j}
+ x̆if̆i(x̆i)[I{d̂(xi) = j} − I{d̆(x̆i) = j}]
∣∣∣ ≤ Mρ/n,
where Mρ depends on M,CX and ρ. The last inequality follows from Assump-
tions 1, 5 and 6.
By McDiarmid’s inequality,
P (|PnXf̂(X)I{d̂(X) = j} − PXf̂(X)I{d̂(X) = j}| ≥ ε) ≤ e−2nε
2/M2ρ .
Then with probability ≥ 1− δ,





For (II), by Cauchy-Schwaz inequality and the boundedness of X,







where the last step follows from Assumption 4. For (III),






≤ M‖f∗ − fm‖2.
For (IV),
|PXf∗(X)I{d̂(X) = j} − PXf∗(X)I{d∗(X) = j}|
= |PXf∗(X)I{d∗(X) = j, d̂(X) = d∗(X)}|
≤ |PXf∗(X)I{d∗(X) = j}I{0 < |f∗(X)| ≤ |f∗(X)− f̂(X)|}|
≤ |P[Xf∗(X)I{d∗(X) = j}]P{0 < |f∗(X)| ≤ |f∗(X)− f̂(X)|}|
≤ |P[Xf∗(X)I{d∗(X) = j}]P[I{0 < |f∗(X)| ≤ ε}I{|f∗(X)− f̂(X)| ≤ ε}








where ‖f‖2 = E{f(x)2}1/2. Choosing the optimal ε as ‖f∗ − f̂‖
2
γ+2
2 , we have
that
|PXf∗(X)I{d̂(X) = j} − PXf∗(X)I{d∗(X) = j}|















Combining the above results, we obtain that with probability ≥ 1− δ,
|μ̂†j − μ
†














Therefore, |μ̂†j − μ
†





We then consider the bound on ‖Σ̂†j − Σ
†
j‖, j = ±1. Let F̂ (X) =∑n
i=1 f̂(Xi)I{d̂(Xi) = j}, Fm(X) =
∑n
i=1 f
m(Xi)I{d̂(Xi) = j} and F ∗(X) =∑n
i=1 f





W (Xi)I{d̂(Xi) = j}∑n
i=1 W (Xi)I{d̂(Xi) = j}
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(X − μ†j)ᵀ(X − μ
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(β̂10 + F̂ u)ᵀ(Σ̂
†





−1 + ρ−1Ip)(β̂10 + F̂ u),
where we use the estimated Σ̂±1, F̂ and β̂10 in M(u). Since u belongs to a
compact set, β̂10 → β10, Σ̂j → Σj and F̂ → F , supu |Mn(u) − M(u)| → 0 in
probability. Given that M(u) has a unique maximizer and u is in a compact
set, we have sup‖u−u∗‖≥ε M(u) < M(u
∗). Hence the conditions of Theorem 5.7
of van der Vaart (1998) are satisfied, and it follows that û → u∗ in probability,
and subsequently β̂1 → β∗1 in probability.
We now show the convergence rate of β̂1 to β
∗
1 . Given that u → M(u) is
twice differentiable at u∗, we have M(u) − M(u∗)  −c‖u − u∗‖2 for all u in
the neighborhood of u∗ and some c > 0, where u∗ is the unique maximizer of










|(Mn −M)(u)− (Mn −M)(u∗)|
















|(Mn −M)(u)− (Mn −M)(u∗)|












n + n−1/2)δ, φ(δ)/δη is
decreasing for any η ∈ (1, 2). In addition, û → u∗ in probability, and û maximize













n + n−1/2), and the desired result follows.
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